End Price Gouging for Medications Act

Bill 118 s 2044, also known as the End Price Gouging for Medications Act, is a piece of legislation currently being considered by the US Congress. The main goal of this bill is to address the issue of price gouging in the pharmaceutical industry, specifically in relation to medications.

The bill aims to prevent pharmaceutical companies from unfairly raising the prices of essential medications, such as insulin and EpiPens, which are necessary for the health and well-being of many Americans. Price gouging occurs when companies significantly increase the prices of these medications without any justification, leading to financial strain for patients who rely on them.

If passed, the End Price Gouging for Medications Act would establish regulations to limit the amount by which pharmaceutical companies can increase the prices of medications. It would also require these companies to provide transparency regarding the costs associated with producing these medications, in order to prevent unjustified price hikes. Additionally, the bill includes provisions to hold pharmaceutical companies accountable for price gouging, including penalties for those found to be in violation of the regulations. This is intended to deter companies from engaging in this harmful practice and protect consumers from being exploited. Overall, the End Price Gouging for Medications Act seeks to ensure that essential medications remain affordable and accessible for all Americans, and to prevent pharmaceutical companies from taking advantage of patients in need. It is an important piece of legislation that addresses a pressing issue in the healthcare industry.